Related Experiment Videos
Management of a perforated levonorgestrel-medicated intrauterine device--a pharmacokinetic study: case report
Ronit Haimov-Kochman1, Hagay Amsalem, Amiram Adoni
1Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, Israel. rkochman@hotmail.com
Abstract:
Intrauterine contraception is a widely used, highly effective method of birth control. Uterine perforation is a serious albeit rare complication with the use of an intrauterine device (IUD). Although uterine perforation by the levonorgestrel-releasing intrauterine system (LNG-IUS) has already been described, no plasma LNG concentrations in this setting were reported. Neither has the management of LNG-IUS been commented on to date. Two months after insertion of an LNG-IUS into a 33-year-old woman, it was noted to be in the peritoneal cavity. Laparoscopy for IUD removal was conducted 5 months after insertion. LNG and sex hormone-binding globulin plasma concentrations were measured prior to and following the laparoscopic removal of the IUD. Intra-peritoneal dislocated LNG-IUS resulted in plasma LNG levels 10 times higher (4.7 nmol/l) than the plasma level of LNG observed with LNG-IUS placed in utero. This high plasma LNG level suppresses ovulation. Therefore a misplaced LNG-IUS should be removed when pregnancy is desired.
Related Concept Videos
Intrauterine Drug Delivery Systems
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Modified-Release Drug Delivery Systems: Influencing Factors